AlphaStocks
6.4
Consider Buy

Amneal Pharmaceuticals, Inc. (AMRX)

Health Care / Pharmaceuticals

S&P SmallCap 600

$12.70

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

#195out of 1127 in Health Care

Is Amneal Pharmaceuticals, Inc. a Good Investment in 2026?

Amneal Pharmaceuticals, Inc. (AMRX) scores 6.4 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates Amneal Pharmaceuticals, Inc. as Strong (7/9). The Graham model is the least favorable, rating it Neutral. Amneal Pharmaceuticals, Inc. currently trades above its estimated fair value of $9, suggesting limited upside at current prices. Amneal Pharmaceuticals, Inc. ranks #195 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E57.3ROE-80.0Market Cap4B

Estimated Fair Value

$8.6547% above

Trading above estimated fair value. P/e of 57x implies high growth expectations.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Strong

7/9

Buffett

Neutral

Business quality & competitive moat

Graham

Neutral

Price vs intrinsic value

Lynch

Attractive

Growth rate vs price (PEG)

Greenblatt

Attractive

Top half (rank 39%)

Frequently Asked Questions

Is Amneal Pharmaceuticals, Inc. (AMRX) a good investment?
Based on AlphaStocks' composite analysis, Amneal Pharmaceuticals, Inc. (AMRX) scores 6.4 out of 10, earning a Consider Buy rating. This is a middle-of-the-pack score with no strong signal either way. Trading above estimated fair value. P/e of 57x implies high growth expectations.
What is Amneal Pharmaceuticals, Inc.'s Piotroski F-Score?
Amneal Pharmaceuticals, Inc.'s Piotroski F-Score status is Strong. The raw score is 7/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is AMRX overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $9, AMRX appears overvalued. The stock currently trades 47% above its estimated fair value. Trading above estimated fair value. P/e of 57x implies high growth expectations.
How does AMRX compare to other Health Care stocks?
Amneal Pharmaceuticals, Inc. ranks #195 out of 1127 stocks in the Health Care sector, placing it in the top 17% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about AMRX?
AlphaStocks evaluates AMRX using five proven investment models. Piotroski: Strong; Buffett: Neutral; Graham: Neutral; Lynch: Attractive; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 6.4/10.

Similar Stocks

PARRFTIAZN

Compare AMRX with

AMRX vs PARRAMRX vs FTIAMRX vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer